ENGLEWOOD, Colo., July 11, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a development stage biopharmaceutical company focused on the discovery and development of a novel therapy aimed at treating common inflammatory conditions for which there are limited treatment options, today announced that its Audit Committee and Board of Directors appointed Moss Adams LLP as the Company's new independent auditor. Moss Adams has served for over 100 years as a fully integrated professional services firm with over 3,200 professionals across more than 25 locations in the western United States.
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE; the "Company"), a pre-revenue development stage biopharmaceutical company announced today that it has suspended patient enrollment in its Phase 3 clinical trial of Ampion ("AP-013") for the treatment of severe osteoarthritis of the knee ("OAK"). The trial focuses on individuals with the most severely diseased OAK, which represents an underserved patient population typically excluded from clinical studies because of the intractable nature of their condition. The average and maximum age of a patient in the AP-013 clinical trial is 65 and 87 years old, respectively. The Centers for Disease Control and Prevention ("CDC") have indicated that older adults, 65 years and older, are at higher risk for severe illness during the current COVID-19 pandemic.
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat prevalent inflammatory conditions announced today that it was featured on a FOX segment titled, "Englewood pharmaceutical company looking to treat COVID-19 patients with anti-inflammatory drug," reported by an affiliated television station in Denver, Colorado. The primary cause of death associated with SARS-Cov-2 ("COVID-19") infection is Acute Respiratory Distress Syndrome ("ARDS"), and there are no approved treatments for ARDS or COVID-19. The segment featured the Company's application to the FDA to study the treatment of COVID-19 induced ARDS with nebulized Ampion.
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat prevalent inflammatory conditions for which limited treatment options exist, announced today that it is preparing an expanded access FDA protocol to study potential benefit of nebulized treatment with Ampion in SARS-Cov-2 ("COVID-19") induced Acute Respiratory Distress Syndrome ("ARDS"), an immediately life-threatening condition.
Investors need to pay close attention to Ampio (AMPE) stock based on the movements in the options market lately.
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment ("SPA") Phase III clinical trial titled "Evaluating the Efficacy and Safety of Ampion™ to treat Adults with Pain Due to Severe Osteoarthritis of the Knee", today announced updates regarding the continued progress of its Phase III AP-013 clinical trial and receipt of its annual audit opinion.
ENGLEWOOD, Colo., Oct. 10, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled "Evaluating the Efficacy and Safety of AmpionTM to treat Adults with Pain Due to Severe Osteoarthritis of the Knee," today announced updates of the continued progress with their Phase III AP-013 clinical trial and their "state-of-the-Art" manufacturing facility. "It is important to note," Ms. Cherevka continued, "in the three randomized single-injection studies previously run by the Company, both reduction in pain and improvement in function were significantly greater for KL 4 patients treated with Ampion vs saline.
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
The Company intends to use the net proceeds from this offering for the full cost of its AP-013 clinical trial, titled "A Randomized, Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of an Intra-Articular Injection of Ampion in Adults with pain Due to Severe Osteoarthritis of the Knee," pursuant to its recently announced Special Protocol Assessment and for other general corporate purposes. The shares of common stock in this offering were offered on a reasonable best efforts, any and all basis pursuant to an effective shelf registration statement.
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) is a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions. As part of this program, the company is developing therapies for patients infected with the SARS-CoV-2 virus ("COVID-19").
The Company intends to use the net proceeds from this offering for the full cost of its AP-013 clinical trial pursuant to its recently announced Special Protocol Assessment and other general corporate purposes. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as the exclusive placement agent for this transaction.
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled "Evaluating the Efficacy and Safety of Ampion™ to treat Adults with Pain Due to Severe Osteoarthritis of the Knee", today announced updates regarding the continued progress of its Phase III AP-013 clinical trial and its manufacturing facility.
If you're interested in Ampio Pharmaceuticals, Inc. (NYSEMKT:AMPE), then you might want to consider its beta (a...
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the development of immunology based therapies for prevalent inflammatory conditions, today announced a manuscript accepted for publication in The Journal of Patient Safety in Surgery that showed Ampion treatment could improve clinical outcomes for COVID-19 patients.
ENGLEWOOD, Colo., Aug. 22, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a special protocol assessment (SPA) phase three clinical trial titled, "A Randomized, Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of an Intra-Articular Injection of Ampion™ in Adults with Pain Due to Severe Osteoarthritis of the Knee," today announced that the Company has retained Torreya Partners LLC as a financial advisor and has appointed Willam Bindley and Bruce E. Terker to a newly formed Transaction Advisory Committee (TAC).
ENGLEWOOD, Colo., July 10, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a development stage biopharmaceutical company focused on the discovery and development of a novel therapy aimed at treating common inflammatory conditions for which there are limited treatment options, today announced that Dan Stokely has been appointed as Chief Financial Officer. Dan Stokely has more than 30 years of experience in finance and accounting and is a Certified Public Accountant.
ENGLEWOOD, Colo., June 14, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) ("Ampio"), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Ampio expects to grant the underwriters a 45-day option to purchase additional shares of common stock offered in the public offering. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.
Ampio (AMPE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
ENGLEWOOD, Colo. , Sept. 17, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) today announced the progress to date in the Company's special protocol assessment (SPA) phase three ...
ENGLEWOOD, Colo., Sept. 18, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) phase three clinical trial titled "Evaluating the Efficacy and Safety of Ampion to treat Adults with Pain Due to Severe Osteoarthritis of the Knee", today announced that Cooley LLP has been engaged to represent Ampio with respect to a potential strategic transaction, as well as related matters.